PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts

BACKGROUND: PARP inhibitors niraparib and talazoparib are FDA approved for special cases of breast cancer. PARP is an interesting repair protein which is frequently affected in cancer cells. We studied the combined action of talazoparib or niraparib with ionizing radiation in melanoma cells and heal...

Descripción completa

Detalles Bibliográficos
Autores principales: Weigert, Verena, Jost, Tina, Hecht, Markus, Knippertz, Ilka, Heinzerling, Lucie, Fietkau, Rainer, Distel, Luitpold V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433076/
https://www.ncbi.nlm.nih.gov/pubmed/32811446
http://dx.doi.org/10.1186/s12885-020-07190-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433076/
https://www.ncbi.nlm.nih.gov/pubmed/32811446
http://dx.doi.org/10.1186/s12885-020-07190-9

Ejemplares similares